Literature DB >> 25792242

Why are cancer drugs so expensive in the United States, and what are the solutions?

Hagop Kantarjian1, S Vincent Rajkumar2.   

Abstract

High cancer drug prices are a worsening trend in cancer care and are affecting patient care and our health care system. In the United States, the average price of cancer drugs for about a year of therapy increased from $5000 to $10,000 before 2000 to more than $100,000 by 2012, while the average household income has decreased by about 8% in the past decade. Further, although 85% of cancer basic research is funded through taxpayers' money, Americans with cancer pay 50% to 100% more for the same patented drug than patients in other countries. Bound by the Hippocratic Oath, oncologists have a moral obligation to advocate for affordable cancer drugs. In this article, we discuss the high cost of cancer drugs, the reasons for these high prices, the implications for patients and the health care system, and potential solutions to the problem.
Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25792242     DOI: 10.1016/j.mayocp.2015.01.014

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  28 in total

Review 1.  Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.

Authors:  Simon B Zeichner; Daniel A Goldstein; Christine Kohn; Christopher R Flowers
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 2.  Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Authors:  S Vincent Rajkumar; Jean Luc Harousseau
Journal:  Blood       Date:  2016-10-14       Impact factor: 22.113

3.  ACMT Position Statement: Addressing the Rising Cost of Prescription Antidotes.

Authors:  Maryann Mazer-Amirshahi; Andrew Stolbach; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2017-11-28

4.  Correction to: ACMT Position Statement: Addressing the Rising Cost of Prescription Antidotes.

Authors:  Maryann Mazer-Amirshahi; Andrew Stolbach; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2018-06

5.  Estimating Public and Patient Savings From Basic Research-A Study of Optical Coherence Tomography in Managing Antiangiogenic Therapy.

Authors:  Matthew A Windsor; Sissi J J Sun; Kevin D Frick; Eric A Swanson; Philip J Rosenfeld; David Huang
Journal:  Am J Ophthalmol       Date:  2017-12-07       Impact factor: 5.258

6.  Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries.

Authors:  Ya-Chen Tina Shih; Ying Xu; Lei Liu; Fabrice Smieliauskas
Journal:  J Clin Oncol       Date:  2017-05-04       Impact factor: 44.544

7.  Chronic Diseases in High-Cost Users of Hospital, Primary Care, and Prescription Medication in the Capital Region of Denmark.

Authors:  Cecilie Goltermann Toxværd; Kirstine Skov Benthien; Anne Helms Andreasen; Ann Nielsen; Merete Osler; Nanna Borup Johansen
Journal:  J Gen Intern Med       Date:  2019-09-11       Impact factor: 5.128

8.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:  Ayalew Tefferi; Hagop Kantarjian; S Vincent Rajkumar; Lawrence H Baker; Jan L Abkowitz; John W Adamson; Ranjana Hira Advani; James Allison; Karen H Antman; Robert C Bast; John M Bennett; Edward J Benz; Nancy Berliner; Joseph Bertino; Ravi Bhatia; Smita Bhatia; Deepa Bhojwani; Charles D Blanke; Clara D Bloomfield; Linda Bosserman; Hal E Broxmeyer; John C Byrd; Fernando Cabanillas; George Peter Canellos; Bruce A Chabner; Asher Chanan-Khan; Bruce Cheson; Bayard Clarkson; Susan L Cohn; Gerardo Colon-Otero; Jorge Cortes; Steven Coutre; Massimo Cristofanilli; Walter J Curran; George Q Daley; Daniel J DeAngelo; H Joachim Deeg; Lawrence H Einhorn; Harry P Erba; Francisco J Esteva; Elihu Estey; Isaiah J Fidler; James Foran; Stephen Forman; Emil Freireich; Charles Fuchs; James N George; Morie A Gertz; Sergio Giralt; Harvey Golomb; Peter Greenberg; Jordan Gutterman; Robert I Handin; Samuel Hellman; Paulo Marcelo Hoff; Ronald Hoffman; Waun Ki Hong; Mary Horowitz; Gabriel N Hortobagyi; Clifford Hudis; Jean Pierre Issa; Bruce Evan Johnson; Philip W Kantoff; Kenneth Kaushansky; David Khayat; Fadlo R Khuri; Thomas J Kipps; Margaret Kripke; Robert A Kyle; Richard A Larson; Theodore S Lawrence; Ross Levine; Michael P Link; Scott M Lippman; Sagar Lonial; Gary H Lyman; Maurie Markman; John Mendelsohn; Neal J Meropol; Yoav Messinger; Therese M Mulvey; Susan O'Brien; Roman Perez-Soler; Raphael Pollock; Josef Prchal; Oliver Press; Jerald Radich; Kanti Rai; Saul A Rosenberg; Jacob M Rowe; Hope Rugo; Carolyn D Runowicz; Brenda M Sandmaier; Alan Saven; Andrew I Schafer; Charles Schiffer; Mikkael A Sekeres; Richard T Silver; Lillian L Siu; David P Steensma; F Marc Stewart; Wendy Stock; Richard Stone; Rainer Storb; Louise C Strong; Martin S Tallman; Michael Thompson; Naoto T Ueno; Richard A Van Etten; Julie M Vose; Peter H Wiernik; Eric P Winer; Anas Younes; Andrew D Zelenetz; Charles A LeMaistre
Journal:  Mayo Clin Proc       Date:  2015-07-23       Impact factor: 7.616

9.  Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.

Authors:  Gregory H Jones; Michael A Carrier; Richard T Silver; Hagop Kantarjian
Journal:  Blood       Date:  2016-01-27       Impact factor: 22.113

10.  Factors Associated With Oncologist Discussions of the Costs of Genomic Testing and Related Treatments.

Authors:  K Robin Yabroff; Jingxuan Zhao; Janet S de Moor; Helmneh M Sineshaw; Andrew N Freedman; Zhiyuan Zheng; Xuesong Han; Ashish Rai; Carrie N Klabunde
Journal:  J Natl Cancer Inst       Date:  2020-05-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.